Benjamin Winkeljann is an engineer and entrepreneur, specializing in drug delivery systems for RNA and pharmaceutical process optimization. He earned his PhD in bioengineering from the Technical University of Munich’s Munich School of Bioengineering. He then joined Ludwig-Maximilians-University Munich’s Department for Pharmacy as a postdoctoral scientist, focusing on simulation-assisted RNA therapeutic formulations. In 2023, Winkeljann became a Group Leader and began his University Lecturer Qualification in Pharmaceutical Technology and Drug Delivery. That same year, he co-founded RNhale GmbH in Munich, where he serves as the CEO. He is also a Principal Investigator at the Comprehensive Pneumology Center Munich (CPC-M)